Drug Profile
IMO 3100
Alternative Names: IMO-3100Latest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen
- Class Anti-inflammatories; Oligonucleotides
- Mechanism of Action Immunomodulators; Toll-like receptor 7 antagonists; Toll-like receptor 9 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperlipidaemia; Inflammatory bowel diseases; Multiple sclerosis; Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus